Erratum to Pantoprazole: a review of its pharmacological properties and therapeutic use in acid-related disorders

Fitton, A.; Wiseman, L.; Bissac, E.

doi:10.1007/bf03259129

Cited by 86 publications

(133 citation statements)

References 0 publications

Supporting

Mentioning

109

Contrasting

Unclassified

Order By: Relevance

“…Novel antipsychotic compounds (second-generation or 'atypical' antipsychotics) such as clozapine (Fitton and Heel, 1990), olanzapine (Fulton and Goa, 1997), and sertindole (Kane and Tamminga, 1997;Azorin et al, 2006) have some beneficial effect on negative symptoms and reduced potential to produce extrapyramidal side effects, but these agents have demonstrated inconsistent effects on cognitive function in patients with schizophrenia. Depending on the type of cognitive domain measured, second-generation antipsychotics have been reported to produce improvement (Mortimer 1997;Meltzer and McGurk, 1999;Keefe et al, 2007), no effect (Hoff et al, 1996;Meltzer and McGurk, 1999), and impairment (Goldberg et al, 1993).…”

Section: Introductionmentioning

confidence: 99%

Reversal of Subchronic PCP-Induced Deficits in Attentional Set Shifting in Rats by Sertindole and a 5-HT6 Receptor Antagonist: Comparison Among Antipsychotics

Rodefer

Nguyen

Karlsson

et al. 2007

Neuropsychopharmacol

115

View full text Add to dashboard Cite

Currently accepted treatments for schizophrenia can effectively control positive symptoms but have limited impact on cognitive deficits in schizophrenia. The purpose of these experiments was to address this unmet need by characterizing the effects of classical and secondgeneration antipsychotics on cognitive impairments associated with schizophrenia. An additional aim was to characterize the part(s) of the pharmacological profile of drugs that were important to reverse deficits. Cognitive deficits were assessed using a frontally mediated attentional set-shifting task in rats that is analogous to tasks used in humans and nonhuman primates that assess executive function. Mirroring findings in patients with schizophrenia, the classical antipsychotic haloperidol was ineffective in treating set-shifting deficits induced by subchronic treatment with phencyclidine (PCP). Similarly, second-generation antipsychotics, risperidone, clozapine, and olanzapine were ineffective. In contrast, selected doses of sertindole and the 5-HT 6 receptor antagonist SB 271046 attenuated PCPinduced set-shifting deficits. Finally, the 5-HT 2A receptor antagonist M100907 was without effect. Further examination revealed that repeated treatment (21 days) with sertindole, but not olanzapine, also was effective in reversing the executive function deficit. These data suggest that the combination of 5-HT 6 antagonistic activity and the absence of antimuscarinic activity may represent key characteristics of the pharmacological profile for improved antipsychotic drugs for schizophrenia.

show abstract

Section: Introductionmentioning

confidence: 99%

Reversal of Subchronic PCP-Induced Deficits in Attentional Set Shifting in Rats by Sertindole and a 5-HT6 Receptor Antagonist: Comparison Among Antipsychotics

Rodefer

Nguyen

Karlsson

et al. 2007

Neuropsychopharmacol

115

View full text Add to dashboard Cite

show abstract

“…1 Diarrhoea was one of the most common adverse events reported in clinical trials with proton pump inhibitors, namely in 3.5% of patients using 30 mg lansoprazole, 1.9% using 20 to 40 mg omeprazole, 1.5% using 40 to 120 mg of pantoprazole and 2.4% using 10 to 20 mg rabeprazole. [1][2][3][4] In patients with an age of 65 years or more, a frequency of diarrhoea of 4.7% is documented. 1 During long-term treatment, diarrhoea occurred in 1.9 to 5% of lansoprazole users compared to 3% of omeprazole users.…”

Section: Introductionmentioning

confidence: 99%

Characteristics of diarrhoea in 10 008 users of lansoprazole in daily practice: which co‐factors contribute?

Claessens

Heerdink

Eijk

et al. 2002

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

SUMMARYPurpose Diarrhoea is one of the most frequently reported adverse events during proton pump inhibitor use in any setting. Because of the limited available information, this study was set up with the aim of assessing the incidence and characteristics of diarrhoea and to investigate possible associated co-factors in proton pump inhibitor users in daily practice. Methods Data were used from a prospective, observational study in which 10 008 lansprazole users were followed over time (1994)(1995)(1996)(1997)(1998). The study was designed according to the SAMM guidelines. A nested case-control design was used to compare proton pump inhibitor users reporting diarrhoea with those reporting no diarrhoea. Results The frequency of diarrhoea was 3.7% and the incidence density 10.7 per 1000 patient months of proton pump inhibitor use. The diarrhoea was most commonly loose and occurred on average 4.4 times per day. The analysis of co-factors revealed that patients with concomitant use of oral antibiotics and patients reporting neurological and/or dermatological adverse events, were at risk of developing diarrhoea during proton pomp inhibitor use. Conclusions In conclusion, diarrhoea was as frequently reported in our study as in clinical trials and observational data of lansoprazole users. We found the concomitant use of oral antibiotics and the reporting of certain other adverse events to be associated with the reporting of diarrhoea during lansoprazole use. Although a relationship with the proton pump inhibitor intake seemed very plausible, we recommend that use of concomitant medicines as a cause of diarrhoea must be taken into consideration in lansoprazole users.

show abstract

“…Pantoprazole has several advantages compared to its analogues (e.g., omeprazole and lansoprazole) such as specific site of binding, greater stability in neutral pH environment, and longer duration of action 6 . Besides, it presents no potential to induce or inhibit the CYP 450 1,2,7 . It is a more selective inhibitor of acid secretion than other proton pump inhibitors 8 .…”

Section: Introductionmentioning

confidence: 99%

Design, in Vitro Evaluation and in Vivo Studies of Novel Delayed Release Tablets of Pantoprazole

Choudhry¹,

Patel²,

Jain³

et al. 2012

Int J of Biomed & Adv Res

View full text Add to dashboard Cite

In an effort to reduce production costs, a simple, direct compression delayed release formulation consisting of pantoprazole was investigated. Pantoprazole is a proton pump inhibitor belongs to group of benzimidazole. It is very efficient for the treatment of gastric and duodenum ulcers. Even in solid state pantoprazole is sensitive to heat, humidity, light and especially to substances containing an acidic group. For such types of drugs, enteric coating added to the formulation tends to avoid the stomach's acidic exposure, delivering them instead to a basic pH environment where they do not degrade, and give their desired action. Subcoating is desirable to protect the enteric coating. Opadry and Acryl-EZE systems have been utilized for subcoating and enteric coating respectively. Delayedrelease tablets with good physical, mechanical and technological properties were obtained with use of different combinations of diluents, binders, superdisintegrants and lubricants. A comparative kinetic study of the present tablets and commercial tablets was established. The value for the similarity factor (f2 = 71.6) suggested that the dissolution profile of the present two delayed-release oral dosage forms are similar. Hixon-Crowell (erosion) kinetic profiles were achieved.

show abstract

Erratum to Pantoprazole: a review of its pharmacological properties and therapeutic use in acid-related disorders

Cited by 86 publications

References 0 publications

Reversal of Subchronic PCP-Induced Deficits in Attentional Set Shifting in Rats by Sertindole and a 5-HT6 Receptor Antagonist: Comparison Among Antipsychotics

Reversal of Subchronic PCP-Induced Deficits in Attentional Set Shifting in Rats by Sertindole and a 5-HT6 Receptor Antagonist: Comparison Among Antipsychotics

Characteristics of diarrhoea in 10 008 users of lansoprazole in daily practice: which co‐factors contribute?

Design, in Vitro Evaluation and in Vivo Studies of Novel Delayed Release Tablets of Pantoprazole

Contact Info

Product

Resources

About